References
- CoatesLCGossecLRamiroSNew GRAPPA and EULAR recommendations for the management of psoriatic arthritisRheumatology20175681251125328077693
- SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
- SmolenJSSchölsMBraunJTreating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task forceAnn Rheum Dis201877131728684559
- ZiegelbauerKKostevKHübingerMThe impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in GermanyRheumatology201857712761281
- Contreras-YáñezICabiedesJVillaARRull-GabayetMPascual-RamosVPersistence on therapy is a major determinant of patient-, physician- and laboratory-reported outcomes in recent-onset rheumatoid arthritis patientsClin Exp Rheumatol201028574875120863447
- CalipGSAdimadhyamSXingSRinconJCLeeWJAnguianoRHMedication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditionsSemin Arthritis Rheum201747215716428410817
- DalénJSvedbomABlackCMTreatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistenceRheumatol Int201636798799526780533
- EbinaKHashimotoMYamamotoWDrug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis – The ANSWER cohort studyPLoS One2018133e019413029543846
- RobertsLTymmsKde JagerJThe CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeInt J Rheumatol2017201718
- FinckhANetoDIannoneFThe impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesRMD Open201511e00004026509062
- KrügerKBurmesterGRWassenbergSBohl-BühlerMThomasMHEffectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in GermanyBMJ Open201886e021082
- HernandezMVSanchez-PiedraCGarcia-MagallonBFactors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registryRheumatol Int201855317
- van den ReekJKievitWGniadeckiRDrug survival studies in dermatology:principles, purposes, and pitfallsJ Invest Dermatol2015135715
- IannoneFGremeseEAtzeniFLongterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictorsJ Rheumatol20123961179118422467933
- LathiaUEwaraEMNantelFImpact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritisPatient Prefer Adherence2017111133114228740368
- SvedbomAStorckCKachrooSGovoniMKhalifaAPersistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritisPatient Prefer Adherence20171171972928435230
- BhoiPBessetteLBellMJTkaczykCNantelFMaslovaKAdherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative databaseBMJ Open201779e015872
- SørensenJHetlandMLAll departments of rheumatology in Denmark. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registryAnn Rheum Dis2015743e1224534758
- ThorneCBensenWGChoquetteDEffectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registryArthritis Care Res201466811421151